{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040584","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.718297+00:00","generated_at":"2026-06-11T21:39:52.048119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M","bullets":["Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.","Gross margin 71.8% vs 65.3%; net loss $1.0M ($0.04/sh) vs $2.9M loss ($0.42/sh) YoY.","Patient pipeline 969 candidates (+27%); 408 new candidates added in Q2 (+57%).","CMS proposed rule may expand brace definition to include MyoPro; Medicare Part B reimbursement anticipated in 6-12 months.","Outlook: modest Q3 YoY growth; full-year product revenue growth target of 20-30% dependent on authorizations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040584","json":"https://secwatch.observer/filing/0000950170-23-040584.json","markdown":"https://secwatch.observer/filing/0000950170-23-040584.md","text":"https://secwatch.observer/filing/0000950170-23-040584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/0000950170-23-040584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/myo-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:39:52.048119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fa46b84d54a0cb2df9433adf33aa4387949b9f0","claim":"MYOMO, INC. reported the second quarter ended June 30, 2023 results: revenue $6.0 million.","evidence_excerpt":"EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/0000950170-23-040584-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$6.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}